Payment overview · 2025
General Payments
$1,266.63
76 reported records · 19 companies
Healthcare provider profile · identity verified
Barry Tedder, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Interventional Cardiology · JONESBORO, AR · NPI 1467457358
Verified facts
What the public records show
CMS Open Payments records show Barry Tedder, M.D. received $1,266.63 in general payments during 2025 across 76 reported records.
Novartis Pharmaceuticals Corporation accounted for 17.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 30 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 314 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 314 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Mounjaro by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 195 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $215.29 | 17.0% | 16 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $198.37 | 15.7% | 25 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $169.98 | 13.4% | 10 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $140.57 | 11.1% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $125.97 | 9.9% | 3 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$57.99 | 4.6% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $51.09 | 4.0% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $45.38 | 3.6% | 2 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $42.14 | 3.3% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $32.35 | 2.5% | 1 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $29.79 | 2.4% | 1 | 2025 |
| W. L. Gore & Associates, Inc. | Unresolved — no canonical attribution shown | $28.90 | 2.3% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $24.22 | 1.9% | 1 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $23.80 | 1.9% | 1 | 2025 |
| Terumo Medical Corporation | Unresolved — no canonical attribution shown | $21.09 | 1.7% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.61 | 1.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.03 | 1.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.26 | 1.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $13.80 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,266.63 | 76 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $215.29 | 16 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $198.37 | 25 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $125.97 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $94.28 | 1 | 2025 |
Source payment records
|
|||||
| PULSESELECT Normalized: pulseselect |
Device | Medtronic, Inc. | $57.99 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $51.09 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $45.38 | 2 | 2025 |
Source payment records
|
|||||
| General - Angiography Normalized: general angiography |
Device | Boston Scientific Corporation | $43.99 | 3 | 2025 |
Source payment records
|
|||||
| Ranger Normalized: ranger |
Device | Boston Scientific Corporation | $40.56 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $32.35 | 1 | 2025 |
Source payment records
|
|||||
| General - Therapies Normalized: general therapies |
Device | Boston Scientific Corporation | $32.01 | 1 | 2025 |
Source payment records
|
|||||
| EVKEEZA Normalized: evkeeza |
Biological | Regeneron Healthcare Solutions, Inc. | $29.79 | 1 | 2025 |
Source payment records
|
|||||
| GORE VIABAHN VBX Balloon Expandable Endo Normalized: gore viabahn vbx balloon expandable endo |
Device | W. L. Gore & Associates, Inc. | $28.90 | 2 | 2025 |
Source payment records
|
|||||
| MITRACLIP Normalized: mitraclip |
Device | Abbott Laboratories | $27.78 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $24.22 | 1 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $23.80 | 1 | 2025 |
Source payment records
|
|||||
| ROTAPRO Normalized: rotapro |
Device | Boston Scientific Corporation | $21.47 | 1 | 2025 |
Source payment records
|
|||||
| AZUR CX DETACHABLE Normalized: azur cx detachable |
Device | Terumo Medical Corporation | $21.09 | 1 | 2025 |
Source payment records
|
|||||
| GLIDESHEATH SLENDER Normalized: glidesheath slender |
Device | Terumo Medical Corporation | $21.09 | 1 | 2025 |
Source payment records
|
|||||
| METACROSS OTW Normalized: metacross otw |
Device | Terumo Medical Corporation | $21.09 | 1 | 2025 |
Source payment records
|
|||||
| R2P MISAGO Normalized: r2p misago |
Device | Terumo Medical Corporation | $21.09 | 1 | 2025 |
Source payment records
|
|||||
| ENSITE PRECISION Normalized: ensite precision |
Device | Abbott Laboratories | $18.51 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $16.61 | 1 | 2025 |
Source payment records
|
|||||
| ELUVIA Normalized: eluvia |
Device | Boston Scientific Corporation | $16.41 | 1 | 2025 |
Source payment records
|
|||||
| EkoSonic Normalized: ekosonic |
Device | Boston Scientific Corporation | $15.54 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.03 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.03 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $14.26 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $13.80 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $13.80 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 195 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 314 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
125 | 39 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
314 | 63 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
314 | 63 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
110 | 25 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
110 | 37 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
195 | 38 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Ezetimibe | Ezetimibe | 888 | 200 |
| Atorvastatin Calcium | Atorvastatin Calcium | 798 | 204 |
| Clopidogrel | Clopidogrel Bisulfate | 534 | 126 |
| Carvedilol | Carvedilol | 498 | 113 |
| Jardiance | Empagliflozin | 314 | 63 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 261 | 91 |
| Repatha Sureclick | Evolocumab | 260 | 77 |
| Lisinopril | Lisinopril | 240 | 71 |
| Furosemide | Furosemide | 216 | 52 |
| Amlodipine Besylate | Amlodipine Besylate | 212 | 57 |
| Eliquis | Apixaban | 195 | 38 |
| Losartan Potassium | Losartan Potassium | 185 | 53 |
| Spironolactone | Spironolactone | 184 | 48 |
| Pioglitazone Hcl | Pioglitazone Hcl | 143 | 35 |
| Metoprolol Succinate | Metoprolol Succinate | 131 | 34 |
| Vascepa | Icosapent Ethyl | 127 | 20 |
| Farxiga | Dapagliflozin Propanediol | 125 | 39 |
| Allopurinol | Allopurinol | 122 | 24 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 118 | 31 |
| Entresto | Sacubitril/Valsartan | 110 | 25 |
| Fenofibrate | Fenofibrate Nanocrystallized | 110 | 26 |
| Ozempic | Semaglutide | 110 | 37 |
| Pantoprazole Sodium | Pantoprazole Sodium | 106 | 27 |
| Metformin Hcl | Metformin Hcl | 96 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 84 | 20 |
| Praluent Pen | Alirocumab | 79 | 27 |
| Cilostazol | Cilostazol | 76 | 19 |
| Ranolazine Er | Ranolazine | 75 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 73 | 19 |
| Prasugrel Hcl | Prasugrel Hcl | 69 | 14 |
| Nitroglycerin | Nitroglycerin | 65 | 39 |
| Sotalol | Sotalol Hcl | 56 | 11 |
| Amiodarone Hcl | Amiodarone Hcl | 54 | 11 |
| Nexlizet | Bempedoic Acid/Ezetimibe | 52 | suppressed |
| Simvastatin | Simvastatin | 48 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 44 | suppressed |
| Xarelto | Rivaroxaban | 44 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 41 | suppressed |
| Ramipril | Ramipril | 40 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 36 | 11 |
| Midodrine Hcl | Midodrine Hcl | 36 | suppressed |
| Potassium Chloride | Potassium Chloride | 30 | suppressed |
| Valsartan | Valsartan | 26 | 11 |
| Trazodone Hcl | Trazodone Hcl | 25 | suppressed |
| Colchicine | Colchicine | 23 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 23 | suppressed |
| Mounjaro | Tirzepatide | 22 | suppressed |
| Omeprazole | Omeprazole | 21 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 21 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 20 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 15 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 14 | 11 |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Verquvo | Vericiguat | 12 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,266.63 · 76 records | Novartis Pharmaceuticals Corporation | AIRSUPRA, AZUR CX DETACHABLE, Dexcom G6 Transmitter, ELIQUIS, ELUVIA, ENSITE PRECISION, EVKEEZA, EkoSonic, FREESTYLE LIBRE 3, GLIDESHEATH SLENDER, GORE VIABAHN VBX Balloon Expandable Endo, General - Angiography, General - Therapies, JARDIANCE, Kerendia, LEQVIO, LINZESS, METACROSS OTW, MITRACLIP, MOUNJARO, NURTEC ODT, PULSESELECT, R2P MISAGO, REPATHA, REXULTI, ROTAPRO, Ranger, SAPIEN 3 Ultra RESILIA, Wegovy, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error